<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35881020</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-1707</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pharmacology research &amp; perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>Acute retigabine-induced effects on myelinated motor axons in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e00983</StartPage><MedlinePgn>e00983</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00983</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.983</ELocationID><Abstract><AbstractText>Altered motor neuron excitability in patients with amyotrophic lateral sclerosis (ALS) has been suggested to be an early pathophysiological mechanism associated with motor neuron death. Compounds that affect membrane excitability may therefore have disease-modifying effects. Through which mechanism(s), these compounds modulate membrane excitability is mostly provided by preclinical studies, yet remains challenging to verify in clinical studies. Here, we investigated how retigabine affects human myelinated motor axons by applying computational modeling to interpret the complex excitability changes in a recent trial involving 18 ALS patients. Compared to baseline, the post-dose excitability differences were modeled well by a hyperpolarizing shift of the half-activation potential of slow potassium (K<sup>+</sup> )-channels (till 2&#xa0;mV). These findings verify that retigabine targets slow K<sup>+</sup> -channel gating and highlight the usefulness of computational models. Further developments of this approach may facilitate the identification of early target engagement and ultimately aid selecting responders leading to more personalized treatment strategies.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Pharmacology Research &amp; Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sleutjes</LastName><ForeName>Boudewijn T H M</ForeName><Initials>BTHM</Initials><Identifier Source="ORCID">0000-0001-6618-3573</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stikvoort Garc&#xed;a</LastName><ForeName>Diederik J L</ForeName><Initials>DJL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovalchuk</LastName><ForeName>Maria O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heuberger</LastName><ForeName>Jules A A C</ForeName><Initials>JAAC</Initials><Identifier Source="ORCID">0000-0001-7202-5088</Identifier><AffiliationInfo><Affiliation>Center for Human Drug Research, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groeneveld</LastName><ForeName>Geert Jan</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Center for Human Drug Research, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franssen</LastName><ForeName>Hessel</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002219">Carbamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010655">Phenylenediamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>12G01I6BBU</RegistryNumber><NameOfSubstance UI="C101866">ezogabine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002219" MajorTopicYN="N">Carbamates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010655" MajorTopicYN="N">Phenylenediamines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">axonal excitability</Keyword><Keyword MajorTopicYN="N">computational modeling</Keyword><Keyword MajorTopicYN="N">mechanism of action</Keyword><Keyword MajorTopicYN="N">target engagement</Keyword></KeywordList><CoiStatement>LHvdB served on the Scientific Advisory Board of Biogen, Cytokinetics, Prinses Beatrix Spierfonds and the Latran foundation. HF reports previous grants from Biogen and personal fees from Shire. JAACH and GJG report grants from Biogen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>10</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35881020</ArticleId><ArticleId IdType="pmc">PMC9318643</ArticleId><ArticleId IdType="doi">10.1002/prp2.983</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2010;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, CJ MD, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2010;8):496&#x2010;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol. 2013;9:65&#x2010;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3633193</ArticleId><ArticleId IdType="pubmed">23626643</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SB, Kiernan MC, Vucic S. Axonal excitability in amyotrophic lateral sclerosis: axonal excitability in ALS. Neurotherapeutics. 2017;14:78&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233634</ArticleId><ArticleId IdType="pubmed">27878516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Shibuya K, Sato Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:734&#x2010;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunes ZI, Kan VWY, Ye X, Liebscher S. Exciting complexity: the role of motor circuit elements in ALS pathophysiology. Front Neurosci. 2020;14:573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311855</ArticleId><ArticleId IdType="pubmed">32625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai Y, Shibuya K, Misawa S, et al. Axonal dysfunction precedes motor neuronal death in amyotrophic lateral sclerosis. Plos One. 2016;11:e0158596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934877</ArticleId><ArticleId IdType="pubmed">27383069</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Misawa S, Kimura H, et al. Increased motor axonal persistent sodium currents predict rapid functional declines in amyotrophic lateral sclerosis. Neurol Clin Neurosci. 2016;4:108&#x2010;111.</Citation></Reference><Reference><Citation>Noto Y, Shibuya K, Vucic S, Kiernan MC. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Rev Neurother. 2016;16:1147&#x2010;1154.</Citation><ArticleIdList><ArticleId IdType="pubmed">27314534</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz JR, Glassmeier G, Cooper EC, et al. KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier. J Physiol. 2006;573:17&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779690</ArticleId><ArticleId IdType="pubmed">16527853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anti&#x2010;convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000;58:591&#x2010;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">10953053</ArticleId></ArticleIdList></Reference><Reference><Citation>Redford KE, Abbott GW. KCNQ potassium channels as targets of botanical folk medicines. Annu Rev Pharmacol Toxicol. 2021;62:447&#x2010;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">34516289</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient&#x2010;derived motor neurons. Cell Rep. 2014;7:1&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk MO, Heuberger JAAC, Sleutjes BTHM, et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double&#x2010;blind, placebo&#x2010;controlled, crossover trial. Clin Pharmacol Ther. 2018;104:1136&#x2010;1145.</Citation><ArticleIdList><ArticleId IdType="pubmed">29672831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Macklin EA, Vucic S, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186&#x2010;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk MO, Franssen H, Scheijmans FEV, Van Schelven LJ, Van Den Berg LH, Sleutjes B. Warming nerves for excitability testing. Muscle Nerve. 2019;60:279&#x2010;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">31241195</ArticleId></ArticleIdList></Reference><Reference><Citation>Howells J, Trevillion L, Bostock H, Burke D. The voltage dependence of I(h) in human myelinated axons. J Physiol. 2012;590:1625&#x2010;1640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413487</ArticleId><ArticleId IdType="pubmed">22310314</ArticleId></ArticleIdList></Reference><Reference><Citation>Howells J, Czesnik D, Trevillion L, Burke D. Excitability and the safety margin in human axons during hyperthermia. J Physiol. 2013;591:3063&#x2010;3080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832120</ArticleId><ArticleId IdType="pubmed">23613528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalchuk MO, Franssen H, van den Berg LH, van Schelven LJ, Sleutjes B. Excitability of motor and sensory axons in multifocal motor neuropathy. Clin Neurophysiol. 2020;131:2641&#x2010;2650.</Citation><ArticleIdList><ArticleId IdType="pubmed">32947198</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018;46:D1091&#x2010;D1106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753190</ArticleId><ArticleId IdType="pubmed">29149325</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander SP, Mathie A, Peters JA, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: ion channels. Br J Pharmacol. 2019;176(suppl 1):S142&#x2010;S228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6844578</ArticleId><ArticleId IdType="pubmed">31710715</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952;117:500&#x2010;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1392413</ArticleId><ArticleId IdType="pubmed">12991237</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman SG, Ritchie JM. Molecular dissection of the myelinated axon. Ann Neurol. 1993;33:121&#x2010;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">7679565</ArticleId></ArticleIdList></Reference><Reference><Citation>Roper J, Schwarz JR. Heterogeneous distribution of fast and slow potassium channels in myelinated rat nerve fibres. J Physiol. 1989;416:93&#x2010;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1189205</ArticleId><ArticleId IdType="pubmed">2558178</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbin&#x2010;Leftwich A, Mossadeq SM, Ha J, Ruchala I, Le AH, Villalba&#x2010;Galea CA. Retigabine holds KV7 channels open and stabilizes the resting potential. J Gen Physiol. 2016;147:229&#x2010;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772374</ArticleId><ArticleId IdType="pubmed">26880756</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatulian L, Brown DA. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol. 2003;549:57&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2342928</ArticleId><ArticleId IdType="pubmed">12702739</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M&#x2010;type potassium currents by the anti&#x2010;convulsant drug retigabine. J Neurosci. 2001;21:5535&#x2010;5545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762632</ArticleId><ArticleId IdType="pubmed">11466425</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first&#x2010;in&#x2010;class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53:412&#x2010;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">22220513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirams GR, Pathmanathan P, Gray RA, Challenor P, Clayton RH. Uncertainty and variability in computational and mathematical models of cardiac physiology. J Physiol. 2016;594:6833&#x2010;6847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5134370</ArticleId><ArticleId IdType="pubmed">26990229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, Kao T, Horvath Z, et al. A common ankyrin&#x2010;G&#x2010;based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J Neurosci. 2006;26:2599&#x2010;2613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675151</ArticleId><ArticleId IdType="pubmed">16525039</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux JJ, Kleopa KA, Cooper EC, Scherer SS. KCNQ2 is a nodal K+ channel. J Neurosci. 2004;24:1236&#x2010;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793582</ArticleId><ArticleId IdType="pubmed">14762142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang PM, Fleckenstein J, Passmore GM, Brown DA, Grafe P. Retigabine reduces the excitability of unmyelinated peripheral human axons. Neuropharmacology. 2008;54:1271&#x2010;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474382</ArticleId></ArticleIdList></Reference><Reference><Citation>Rundfeldt C. The new anticonvulsant retigabine (D&#x2010;23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol. 1997;336:243&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">9384239</ArticleId></ArticleIdList></Reference><Reference><Citation>Franssen H. The node of Ranvier in multifocal motor neuropathy. J Clin Immunol. 2014;34(suppl 1):S105&#x2010;S111.</Citation><ArticleIdList><ArticleId IdType="pubmed">24801202</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>